Richard Conway is a Clinical Associate Professor at Trinity College Dublin and a consultant rheumatologist at St. James’s Hospital in Ireland. His research focuses on vasculitis, polymyalgia ...

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

Intracranial GCA appears to be more common than previously thought and is linked to higher rates of stroke and mortality.

Patients with giant cell arteritis have a greater risk for aortic complications than those with polymyalgia rheumatica.

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 SELECT-GCA trial.

DESTIN, Fla. — An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according to a speaker at the Congress of Clinical Rheumatology ...

The Bears were flat against Lehigh Valley in Game 2 of their best-of-five Atlantic Division semifinal series at Giant Center on Friday night. Head coach Todd Nelson knew it, and so did team ...

The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the first new approval for the condition since tocilizumab in 2017, according ...

Rinvoq approved for giant cell arteritis; telehealth companies collaborate with Novo Nordisk for Wegovy access; epidermolysis bullosa wound healing treatment approved; Imaavy approved for gMG ...

With the 2025 NFL draft in the books, teams may soon begin trimming their roster of players where the draft addressed depth and hence created an overflow. According to a new analysis by Pro ...

Chicago-based drugmaker AbbVie has announced the US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), ...